戻る
BeOne Medicines AG (6160.HK)価格
6160.HK 株価推移チャート
BEONE MEDICINES (6160.HK)
BeOne Medicines AG
HK$198
-1%
$-2
休場: Jan 20, 16:00:00 HKT
主要データ
前終値
$200.4
始値
$200
当日レンジ
$197 - $200.4
52週レンジ
$115.8 - $229.4
取引高
1.3M
平均取引高
3.9M
1株当たり利益(TTM)
0.31
配当利回り
--
時価総額
$262.0B
BEONE MEDICINESとは何ですか？
BeOne Medicines AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Basel, Basel-Stadt and currently employs 11,075 full-time employees. The company went IPO on 2016-03-02. BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. The company is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.